Zhonghua Wang

Shanghai Medical College of Fudan University — China

Medicine · Health Sciences

24h-index2.0kcitations107works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(35), HER2/EGFR in Cancer Research(31), Advanced Breast Cancer Therapies(27), Breast Cancer Treatment Studies(23), Cancer Immunotherapy and Biomarkers(19)

Publications107 total

Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)
Molecular Cancer·2025Open Access
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial
Cancer Cell·2025
CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer
Molecular Therapy·2025· 1 citedOpen Access
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
Nature Medicine·2025· 11 cited
Abstract GS3-06: Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial
Clinical Cancer Research·2025· 1 cited
Abstract PS3-01: Tislelizumab plus sitravatinib and nab-paclitaxel in patients with untreated locally recurrent or metastatic triple negative breast cancer (TNBC): updated efficacy and safety results
Clinical Cancer Research·2025
Abstract P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial
Clinical Cancer Research·2025
Abstract GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial
Clinical Cancer Research·2025
Abstract P2-09-17: Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/ HER2- advanced breast cancer: the Linux trial
Clinical Cancer Research·2025
Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial
The Oncologist·2025· 1 citedOpen Access
Efficacy and safety of RC48-ADC in triple-negative breast cancer subtypes: FUSCC-TNBC-umbrella trial results.
Journal of Clinical Oncology·2025
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial
BMJ·2024· 14 citedOpen Access
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
BMC Cancer·2024· 10 citedOpen Access
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
British Journal of Cancer·2024· 5 citedOpen Access
Does integrated health management within a county medical consortium improve rural type 2 diabetic patients’ self-management behavior and quality of life? An empirical analysis from Eastern China
BMC Public Health·2024· 4 citedOpen Access
Abstract PO1-06-12: Phase II study of sitravatinib plus tislelizumab with or without nab-paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer
Cancer Research·2024
Abstract PO1-14-07: Programme of mast cell subsets to potentiate breast cancer immunotherapy: from bed to bench to bed (the phase 2 platform RENAISSANCE trial)
Cancer Research·2024
Abstract PO1-15-08: Genomic characterization of triple-negative breast cancer metastases reveals PKD1 as a novel biomarker for immunotherapy
Cancer Research·2024
Abstract PO2-03-05: Neoadjuvant anthracycline followed by Toripalimab combined with nab-paclitaxel in patients with stage IIA-IIIC triple negative breast cancer (NeoTENNIS): efficacy and safety results of a phase II study
Cancer Research·2024
Association of lipopolysaccharide with new-onset atrial fibrillation in ST-segment elevation myocardial infarction
Heliyon·2024· 2 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Biyun Wang(16), Xichun Hu(15), Jian Zhang(13), Leiping Wang(13), Jun Cao(11), Zhimin Shao(8), Yi‐Zhou Jiang(7), Jiong Wu(7), Fangfang Lv(6), Song‐Yang Wu(5), Li Chen(5), Lei Fan(5), Wentao Yang(5), Guang‐Yu Liu(5), Ke‐Da Yu(5), Xiu-Zhi Zhu(5), Zhi‐Ming Shao(5), Xinmin Zhao(5), Si Sun(4), Xiaomao Guo(4)